Preliminary results of preoperative chemoradiotherapy with consolidating chemotherapy in patients with locally advanced rectal cancer
PDF (Русский)

Keywords

LOCALLY ADVANCED RECTAL CANCER
CHEMORADIOTHERAPY
CONSOLIDATING CHEMOTHERAPY
COMPLETE CLINICAL AND MORPHOLOGICAL TUMOR RESPONSE

How to Cite

Rasulov, A., Kuzmichev, D., Polynovskiy, A., Aliev, V., Tkachev, S., Kozlov, N., Mamedly, Z., & Suraeva, Y. (2017). Preliminary results of preoperative chemoradiotherapy with consolidating chemotherapy in patients with locally advanced rectal cancer. Voprosy Onkologii, 63(6), 900–906. https://doi.org/10.37469/0507-3758-2017-63-6-900-906

Abstract

Preliminary results of complex treatment of patients with locally advanced rectal cancer with preoperative chemoradio- therapy (CRT) and consolidating chemotherapy (CT) are dis- cussed in the article. The study includes 89 patients of a stage T3 (CRM +) - 4N0-2M0 of the tumor process. In group “A” there was performed preoperative CRT in an isozedosis of 56 Gy against a background of CT by capecitabine 825 mg / m2 twice daily per os with consolidating CT (2 courses of XELOX). In group “B” there was conducted a similar treat- ment without consolidating CT. Group “A” consisted of 49 patients, group “B” - 40 patients. In 9 (18.4%) patients of group “A” a complete clinical response was diagnosed in the follow-up survey, which was the reason for abstinence from surgical treatment and they were taken for dynamic observa- tion. In 9 of 40 (22.5%) operated patients from group “A” there was noted a clinically significant complete morphologi- cal response in tumor (T0N0). In the control group “B” no complete clinical response was achieved in any patient. A complete morphological response in tumor was recorded in 5 of 40 (12.5%) (T0N0) operated patients. A 2-year recurrence- free survival in group “A” was 91.4%, in group B - 70.1%. Locoregional relapses, after treatment in group “A”, were not currently registered, in group “B” this indicator was 2.5%. The frequency of distant metastasis in the study groups was 2.1% and 7.5%, respectively. The average life expectancy was 13.1 months. Preliminary results confirmed strengthening of anti- cancer effect of consolidating CT after prolonged CRT, which was manifested in an increase in the frequency of complete clinical and morphological regression of tumor and, accord- ingly, an improvement of long-term results. A complete clinical response, achieved in every fifth patient, allowed refraining from a disabling operation and saved a quality of life.

https://doi.org/10.37469/0507-3758-2017-63-6-900-906
PDF (Русский)

References

Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2009 году // Вестник РОНЦ им. Н.Н. Блохина РАМН. - 2010. - № 3.

An X., Lin X., Wang F. et al. Short term results of neoadjuvant chemoradiotherapy with fluoropyrimidine alone or in combination with oxaliplatin in locally advanced rectal cancer: a meta analysis // Eur. J. Cancer. - 2013. - Vol. 49(4). - P. 843-851.

Capirci C., Valentini V., Cionini L. et al. Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: long-term analysis of 566 ypCR patients // Int. J. Radiat. Oncol. Biol. Phys. - 2008. - Vol. 72. - № 1. - P. 99-107.

Chand M., Rasheed S., Heald R. et al. Adjuvant chemotherapy may improve disease-free survival in patients with mrEMVI-positive rectal cancer following chemoradiation // Colorectal Dis. - 2016.

Chang J., Ormerod M., Powles T. et al. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma // Cancer. - 2000. - Vol. 89 (11). - P 2145-2152.

Dellas K., Buller J., Görtz G. et al. Analysis of bevacizumab-based preoperative radiochemotherapy in patients with locally advanced rectal cancer on surgery-associated spectrum of complications // Ann Surg Oncol. - 2014. - Vol. 21(4). - P. 1352-1360.

Dellas K., Höhler T., Reese T. et al. Phase II trial of preoperative radiochemotherapy with concurrent bevacizumab, capecitabine and oxaliplatin in patients with locally advanced rectal cancer // Radiat Oncol. - 2013. - Vol. 8. - P. 90.

Gamaleldin M., Church J., Stocchi L. et al. Is routine use of adjuvant chemotherapy for rectal cancer with complete pathological response justified? // Am J. Surg. - 2017. - Vol. 213(3). - P. 478-483.

Gao Y., Zhang X., An X. et al. Oxaliplatin and capecitabine concomitant with neoadjuvant radiotherapy and extended to the resting period in high risk locally advanced rectal cancer // Strahlenther. Onkol. - 2014. - Vol. 190. - P. 158-164.

Garcia-Aguilar J., Smith D., Avila K. et al. Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial // Ann Surg. - 2011. - Vol. 254. - P. 97-102.

Gollins S., Myint S., Susnerwala S. et al. Preoperative downstaging chemoradiation with concurrent irinotecan and capecitabine in MRI-defined locally advanced rectal cancer: a phase I trial (NWCOG-2) // Br. J. Cancer. - 2009. - Vol. 101(6). - P 924-934.

Habr-Gama A., Perez R., Sabbaga J. et al. Increasing the rates of complete response to neoadjuvant chemoradiotherapy for distal rectal cancer: results of a prospective study using additional chemotherapy during the resting period // Dis Colon Rectum. - 2009. - Vol. 52. - P. 1927-1934.

Iles S., Gollins S., Susnerwala S. Irinotecan 5-fluorouracil with concomitant pre-operative radiotherapy in locally advanced non-resectable rectal cancer: a phase I/II study // Br. J. Cancer. - 2008 - Vol. 98(7). - P. 1210-1216.

Jalil O., Claydon L., Arulampalam T. Review of Neoadjuvant Chemotherapy Alone in Locally Advanced Rectal Cancer // J. Gastrointest Cancer. - 2015. - Vol. 46(3). - P. 219-236.

Jiaolin Z., Huizhong Q., Guole L., Yuchao L. Is adjuvant chemotherapy necessary for patients with pathological complete response after neoadjuvant chemoradiotherapy and radical surgery in locally advanced rectal cancer? Long-term analysis of 40 ypCR patients at a single center // International Journal of Colorectal Disease. - 2016. - Vol. 31(6). - P. 1163-1168.

Jung K., Kim H., Park J. et al. Adjuvant chemotherapy after neoadjuvant chemoradiation and curative resection for rectal cancer: is it necessary for all patients? // J Surg Oncol. - 2015. - Vol. 111(4). - P. 439-444.

Kennecke H., Berry S., Wong R. et al. Pre-operative beva-cizumab, capecitabine, oxaliplatin and radiation among patients with locally advanced or low rectal cancer: a phase II trial // Eur. J. Cancer. - 2012. - Vol. 48. - P. 37-45.

Kim N., Baik S., Seong J. et al. Oncologic outcomes after neoadjuvant chemoradiation followed by curative resection with tumor-specific mesorectal excision for fixed locally advanced rectal cancer: Impact of postirradiated pathologic downstaging on local recurrence and survival // Ann Surg. - 2006. - Vol. 244(6). - P. 1024-1030.

Kuo L., Liu M., Jian J. et al. Is final TNM staging a predictor for survival in locally advanced rectal cancer after preoperative chemoradiation therapy? // Ann Surg. Oncol. - 2007. - Vol. 14. - P 2766-2772.

Landry J., Feng Y., Prabhu R. et al. Phase II Trial of Preoperative Radiation With Concurrent Capecitabine, Oxaliplat-in, and Bevacizumab Followed by Surgery and Postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in Patients With Locally Advanced Rectal Cancer: 5-Year Clinical Outcomes ECOG-ACRIN Cancer Research Group E3204 // Oncologist. - 2015. - Vol. 20(6). - P. 615-616.

Maas M., Nelemans P., Valentini V. et al. Long-term outcome in patients with a pathological complete response after chemoradiation for rectal cancer: a pooled analysis of individual patient data // Lancet Oncol. - 2010. - Vol. 11. - № 9. - P. 835-844.

Martin S., Heneghan H., Winter D. Systematic review and meta-analysis of outcomes following pathological complete response to neoadjuvant chemoradiotherapy for rectal cancer // Br. J. Surg. - 2012. - Vol. 99. - № 7. - P. 918-928.

Medical Research Council Rectal Cancer Working Party. Randomised trial of surgery alone versus radiotherapy followed by surgery for potentially operable locally advanced rectal cancer. // Lancet. - 1996. - Vol. 48(9042). - P. 1605-1610.

McCarthy K., Pearson K., Fulton R. et al. Pre-operative chemoradiation for non-metastatic locally advanced rectal cancer // Cochrane Database Syst Rev. - 2012. - Vol. 12. - CD008368.

Musio D., De Felice F., Bulzonetti N. et al. Neoadjuvant-intensified treatment for rectal cancer: time to change? // World J. Gastroenterol. - 2013. - Vol. 19(20). - P. 3052-3061.

National Cancer Comprehensive Network. Clinical practice guidelines in oncology: rectal cancer.v 2. - 2012. URL: http://www.nccn.org

Nogue M., Salud A., Vicente P. et al. Addition of beva-cizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study // Oncologist. - 2011. - Vol. 16. - P. 614-620.

Petersen S., Harling H., Kirkeby L. et al. Postoperative adjuvant chemotherapy in rectal cancer operated for cure // Cochrane Database Syst Rev. - 2012. - Vol. 3. - CD004078.

Quah H., Chou J., Gonen M. et al. Pathologic stage is most prognostic of disease-free survival in locally advanced rectal Cancer patients after preoperative chemoradiation // Cancer. - 2008. - Vol. 113. - P. 57-64.

Roh M., Yothers G., O'Connell M. et al. The impact of capecitabine and oxaliplatin in the preoperative multimodality treatment in patients with carcinoma of the rectum // J. Clin. Oncol. - 2011. - abstr 3503.

Stewart B., Wild C. World Cancer Report // IARC Nonserial Publication, 2014. - 630 pages.

Sun Y, Chi P., Lin H. et al. Analysis of risk factors of distant metastasis in rectal cancer patients who received total mesorectal excision following neoadjuvant chemo-radiotherapy // Zhonghua Wei Chang Wai Ke Za Zhi. - 2016. - Vol. 19(4). - P. 436-441.

Tepper J., Wang A. Improving local control in rectal cancer: Radiation sensitizers or radiation dose? // J. Clin. Oncol. - 2010. - Vol. 28(10). - P. 1623-1624.

The Beyond TME Collaborative // Br J Surg. - 2013. - Vol. 100(8). - P. 1009-1014.

Zampino M., Magni E., Leonardi M. et al. Capecitabine initially concomitant to radiotherapy then perioperatively administered in locally advanced rectal cancer // Int. J. Radiat. Oncol. Biol Phys. - 2009. - Vol. 75. - P. 421-427.

Wang C., Liang J., Tsai C. et al. Neoadjuvant bevacizumab and chemoradiotherapy in locally advanced rectal cancer: early outcome and technical impact on toxicity // World J. Surg. Oncol. - 2014. - Vol. 2. - P. 329.

Wen B., Zhang L., Wang C. et al. Prognostic significance of clinical and pathological stages on locally advanced rectal carcinoma after neoadjuvant chemoradiotherapy // Radiat. Oncol. - 2015. - Vol. 10. - P. 124.

Wong R., Tandan V., De Silva S. et al. Pre-operative radiotherapy and curative surgery for the management of localized rectal carcinoma // Cochrane Database Syst Rev. - 2007. - Vol. (2). - CD002102.

Xu Z., Mohile S., Tejani M. et al. Poor compliance with adjuvant chemotherapy use associated with poorer survival in patients with rectal Cancer: An NCDB analysis // Cancer. - 2017. - Vol. 123(1). - P. 52-61.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

© АННМО «Вопросы онкологии», Copyright (c) 2017